ArticleBioImpacts : BI2025

Nanobody-functionalized liposomal doxorubicin: A novel strategy for angiogenesis suppression via VEGFR2 targeting.

Aezam Akbari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.